Esomeprazole for the treatment of erosive esophagitis in children: an international, multicenter, randomized, parallel-group, double-blind (for dose) study

Vasundhara Tolia, Nader N Youssef, Mark A Gilger, Barry Traxler, Marta Illueca, Vasundhara Tolia, Nader N Youssef, Mark A Gilger, Barry Traxler, Marta Illueca

Abstract

Background: Acid suppression with a proton pump inhibitor is standard treatment for gastroesophageal reflux disease and erosive esophagitis in adults and increasingly is becoming first-line therapy for children aged 1-17 years. We evaluated endoscopic healing of erosive esophagitis with esomeprazole in young children with gastroesophageal reflux disease and described esophageal histology.

Methods: Children aged 1-11 years with endoscopically or histologically confirmed gastroesophageal reflux disease were randomized to esomeprazole 5 or 10 mg daily (< 20 kg) or 10 or 20 mg daily (> or = 20 kg) for 8 weeks. Patients with erosive esophagitis underwent an endoscopy after 8 weeks to assess healing of erosions.

Results: Of 109 patients, 49% had erosive esophagitis and 51% had histologic evidence of reflux esophagitis without erosive esophagitis. Of the 45 patients who had erosive esophagitis and underwent follow-up endoscopy, 89% experienced erosion resolution. Dilation of intercellular space was reported in 24% of patients with histologic examination.

Conclusions: Esomeprazole (0.2-1.0 mg/kg) effectively heals macroscopic and microscopic erosive esophagitis in this pediatric population with gastroesophageal reflux disease. Dilation of intercellular space may be an important histologic marker of erosive esophagitis in children.

Trial registration: D9614C00097; ClinicalTrials.gov identifier NCT00228527.

Figures

Figure 1
Figure 1
Patient disposition. EE: erosive esophagitis.
Figure 2
Figure 2
Endoscopic healing status of erosive esophagitis after 8 weeks of esomeprazole treatment. *Of 53 patients with erosive esophagitis at baseline, eight did not have a final endoscopy.

References

    1. Chitkara DK, Talley NJ, Weaver AL, Katusic SK, De Schepper H, Rucker MJ, Locke GR. Incidence of presentation of common functional gastrointestinal disorders in children from birth to 5 years: a cohort study. Clin Gastroenterol Hepatol. 2007;5:186–191. doi: 10.1016/j.cgh.2006.06.012.
    1. El-Serag HB, Bailey NR, Gilger M, Rabeneck L. Endoscopic manifestations of gastroesophageal reflux disease in patients between 18 months and 25 years without neurological deficits. Am J Gastroenterol. 2002;97:1635–1639. doi: 10.1111/j.1572-0241.2002.05820.x.
    1. Gilger MA, El-Serag HB, Gold BD, Dietrich CL, Tsou V, McDuffie A, Shub MD. Prevalence of endoscopic findings of erosive esophagitis in children: a population-based study. J Pediatr Gastroenterol Nutr. 2008;47:141–146. doi: 10.1097/MPG.0b013e31815eeabe.
    1. Rudolph CD, Mazur LJ, Liptak GS, Baker RD, Boyle JT, Colletti RB, Gerson WT, Werlin SL. Guidelines for evaluation and treatment of gastroesophageal reflux in infants and children: recommendations of the North American Society for Pediatric Gastroenterology and Nutrition. J Pediatr Gastroenterol Nutr. 2001;32(suppl 2):S1–S31. doi: 10.1097/00005176-200100002-00001.
    1. Dahms BB. Reflux esophagitis: sequelae and differential diagnosis in infants and children including eosinophilic esophagitis. Pediatr Dev Pathol. 2004;7:5–16. doi: 10.1007/s10024-003-0203-5.
    1. Ravelli AM, Villanacci V, Ruzzenenti N, Grigolato P, Tobanelli P, Klersy C, Rindi G. Dilated intercellular spaces: a major morphological feature of esophagitis. J Pediatr Gastroenterol Nutr. 2006;42:510–515. doi: 10.1097/01.mpg.0000215312.78664.b9.
    1. DeVault KR, Castell DO. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol. 2005;100:190–200. doi: 10.1111/j.1572-0241.2005.41217.x.
    1. Kahrilas PJ, Falk GW, Johnson DA, Schmitt C, Collins DW, Whipple J, D'Amico D, Hamelin B, Joelsson B. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial. The Esomeprazole Study Investigators. Aliment Pharmacol Ther. 2000;14:1249–1258. doi: 10.1046/j.1365-2036.2000.00856.x.
    1. Richter JE, Kahrilas PJ, Johanson J, Maton P, Breiter JR, Hwang C, Marino V, Hamelin B, Levine JG. Esomeprazole Study Investigators. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial. Am J Gastroenterol. 2001;96:656–665. doi: 10.1111/j.1572-0241.2001.03600.x.
    1. Castell DO, Kahrilas PJ, Richter JE, Vakil NB, Johnson DA, Zuckerman S, Skammer W, Levine JG. Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am J Gastroenterol. 2002;97:575–583. doi: 10.1111/j.1572-0241.2002.05532.x.
    1. Fennerty MB, Johanson JF, Hwang C, Sostek M. Efficacy of esomeprazole 40 mg vs. lansoprazole 30 mg for healing moderate to severe erosive oesophagitis. Aliment Pharmacol Ther. 2005;21:455–463. doi: 10.1111/j.1365-2036.2005.02339.x.
    1. Labenz J, Armstrong D, Lauritsen K, Katelaris P, Schmidt S, Schütze K, Wallner G, Juergens H, Preiksaitis H, Keeling N, Nauclér E, Eklund S. Expo Study Investigators. A randomized comparative study of esomeprazole 40 mg versus pantoprazole 40 mg for healing erosive oesophagitis: the EXPO study. Aliment Pharmacol Ther. 2005;21:739–746. doi: 10.1111/j.1365-2036.2005.02368.x.
    1. Zhao J, Li J, Hamer-Maansson JE, Andersson T, Fulmer R, Illueca M, Lundborg P. Pharmacokinetic properties of esomeprazole in children aged 1 to 11 years with symptoms of gastroesophageal reflux disease: a randomized, open-label study. Clin Ther. 2006;28:1868–1876. doi: 10.1016/j.clinthera.2006.11.012.
    1. Gilger MA, Tolia V, Vandenplas Y, Youssef NN, Traxler B, Illueca M. Safety and tolerability of esomeprazole in children with gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr. 2008;46:524–533. doi: 10.1097/MPG.0b013e318176b2cb.
    1. Lundell LR, Dent J, Bennett JR, Armstrong D, Galmiche JP, Johnson F, Hongo M, Richter JE, Spechler SJ, Tytgat GN, Wallin L. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut. 1999;45:172–180. doi: 10.1136/gut.45.2.172.
    1. Liacouras CA, Wenner WJ, Brown K, Ruchelli E. Primary eosinophilic esophagitis in children: successful treatment with oral corticosteroids. J Pediatr Gastroenterol Nutr. 1998;26:380–385. doi: 10.1097/00005176-199804000-00004.
    1. Ruchelli E, Wenner W, Voytek T, Brown K, Liacouras C. Severity of esophageal eosinophilia predicts response to conventional gastroesophageal reflux therapy. Pediatr Dev Pathol. 1999;2:15–18. doi: 10.1007/s100249900084.
    1. Gilger MA, El-Serag HB, Dietrich CL, Gold BD, Hassall EG. Endoscopic manifestations of erosive esophagitis in children [abstract] Gastrointest Endosc. 2004;59:143. doi: 10.1016/S0016-5107(04)00691-1.
    1. Gupta SK, Fitzgerald JF, Chong SKF, Croffie JM, Collins MH. Vertical lines in distal esophageal mucosa (VLEM): a true endoscopic manifestation of esophagitis in children? Gastrointest Endosc. 1997;45:485–489. doi: 10.1016/S0016-5107(97)70178-0.
    1. Squires RH Jr, Colletti RB. Indications for pediatric gastrointestinal endoscopy: a medical position statement of the North American Society for Pediatric Gastroenterology and Nutrition. J Pediatr Gastroenterol Nutr. 1996;23:107–110. doi: 10.1097/00005176-199608000-00002.
    1. Winter HS, Madara JL, Stafford RJ, Grand RJ, Quinlan JE, Goldman H. Intraepithelial eosinophils: a new diagnostic criterion for reflux esophagitis. Gastroenterology. 1982;83:818–823.
    1. Black DD, Haggitt RC, Orenstein SR, Whitington PF. Esophagitis in infants. Morphometric histological diagnosis and correlation with measures of gastroesophageal reflux. Gastroenterology. 1990;98:1408–1414.
    1. Shub MD, Ulshen MH, Hargrove CB, Siegal GP, Groben PA, Askin FB. Esophagitis: a frequent consequence of gastroesophageal reflux in infancy. J Pediatr. 1985;107:881–884. doi: 10.1016/S0022-3476(85)80180-3.
    1. Ismail-Beigi F, Horton PF, Pope CE. Histological consequences of gastroesophageal reflux in man. Gastroenterology. 1970;58:163–174.
    1. Ismail-Beigi F, Pope CE. Distribution of the histological changes of gastroesophageal reflux in the distal esophagus of man. Gastroenterology. 1974;66:1109–1113.
    1. Solcia E, Villani L, Luinetti O, Trespi E, Strada E, Tinelli C, Fiocca R. Altered intercellular glycoconjugates and dilated intercellular spaces of esophageal epithelium in reflux disease. Virchows Arch. 2000;436:207–216. doi: 10.1007/s004280050032.
    1. Croom KF, Scott LJ. Lansoprazole: in the treatment of gastro-oesophageal reflux disease in children and adolescents. Drugs. 2005;65:2129–2135. doi: 10.2165/00003495-200565150-00005.
    1. De Giacomo C, Bawa P, Franceschi M, Luinetti O, Fiocca R. Omeprazole for severe reflux esophagitis in children. J Pediatr Gastroenterol Nutr. 1997;24:528–532. doi: 10.1097/00005176-199705000-00007.
    1. Faure C, Michaud L, Khan Shaghaghi E, Popon M, Laurence M, Mougenot JF, Hankard R, Navarro J, Jacoz-Aigrain E. Lansoprazole in children: pharmacokinetics and efficacy in reflux oesophagitis. Aliment Pharmacol Ther. 2001;15:1397–1402. doi: 10.1046/j.1365-2036.2001.01076.x.
    1. Franco MT, Salvia G, Terrin G, Spadaro R, De Rosa I, Iula VD, Cucchiara S. Lansoprazole in the treatment of gastro-oesophageal reflux disease in childhood. Dig Liver Dis. 2000;32:660–666. doi: 10.1016/S1590-8658(00)80326-6.
    1. Hassall E, Israel D, Shepherd R, Radke M, Dalväg A, Sköld B, Junghard O, Lundborg P. Omeprazole for treatment of chronic erosive esophagitis in children: a multicenter study of efficacy, safety, tolerability and dose requirements. International Pediatric Omeprazole Study Group. J Pediatr. 2000;137:800–807. doi: 10.1067/mpd.2000.109607.
    1. Madrazo-de la Garza A, Dibildox M, Vargas A, Delgado J, Gonzalez J, Yañez P. Efficacy and safety of oral pantoprazole 20 mg given once daily for reflux esophagitis in children. J Pediatr Gastroenterol Nutr. 2003;36:261–265. doi: 10.1097/00005176-200302000-00019.
    1. Tolia V, Bishop PR, Marc Tsou V, Gremse D, Soffer EF, Comer GM. Members of the 322 Study Group. Multicenter, randomized, double-blind study comparing 10, 20 and 40 mg pantoprazole in children (5-11 years) with symptomatic gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr. 2006;42:384–391. doi: 10.1097/01.mpg.0000214160.37574.d3.
    1. Tolia V, Ferry G, Gunasekaran T, Huang B, Keith R, Book L. Efficacy of lansoprazole in the treatment of gastroesophageal reflux disease in children. J Pediatr Gastroenterol Nutr. 2002;35(suppl 4):S308–S318.
    1. Vandenplas Y, Ashkenazi A, Belli D, Boige N, Bouquet J, Cadranel S, Cezard JP, Cucchiara S, Dupont C, Geboes K, Gottrand F, Heymans HSA, Jasinski C, Kneepkens CMF, Koletzko S, Milla P, Mougenot JF, Nusslé D, Navarro J, Newell SJ, Olafsdottir E, Peeters S, Ravelli A, Polanco I, Sandhu BK, Tolboom J. A proposition for the diagnosis and treatment of gastro-oesophageal reflux disease in children: a report from a working group on gastro-oesophageal reflux disease. Working Group of the European Society of Paediatric Gastro-enterology and Nutrition (ESPGAN) Eur J Pediatr. 1993;152:704–711. doi: 10.1007/BF01953980.
    1. Youssef NN, Orenstein SR. Gastroesophageal reflux disease in children. Clin Perspect Gastroenterol. 2001;Jan/Feb:11–17.
    1. International Conference on Harmonisation (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline: Clinical Investigation for Medicinal Products in the Pediatric Population. 2000.
    1. Tolia V, Youssef N, Belknap W, Gilger M, Traxler B, Illueca M. Treatment of erosive esophagitis with esomeprazole in children with gastroesophageal reflux disease. Poster presented at North American Society for Pediatric Gastroenterology, Hepatology, & Nutrition (NASPGHAN) Annual Meeting, October 19-22, 2006, Orlando, FL.
    1. Tolia V, Youssef N, Belknap W, Gilger M, Traxler B, Illueca M. Treatment of erosive esophagitis with esomeprazole in children with gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr. 2006;43:E20.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner